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Abstract
Purpose To evaluate the potential of ALLN-177, an orally administered, oxalate-specific enzyme therapy to reduce urine 
oxalate (UOx) excretion in patients with secondary hyperoxaluria.
Methods Sixteen male and female subjects with both hyperoxaluria and a kidney stone history were enrolled in an open-
label study. Subjects continued their usual diets and therapies. During a 3-day baseline period, two 24-h (24-h) urines were 
collected, followed by a 4-day treatment period with ALLN-177 (7,500 units/meal, 3 × day) when three 24-h urines were 
collected. The primary endpoint was the change in mean 24-h UOx from baseline. Safety assessments and 24-h dietary 
recalls were performed throughout.
Results The study enrolled 5 subjects with enteric hyperoxaluria and 11 with idiopathic hyperoxaluria. ALLN-177 was well 
tolerated. Overall mean (SD) UOx decreased from 77.7 (55.9) at baseline to 63.7 (40.1) mg/24 h while on ALLN-177 therapy, 
with the mean reduction of 14 mg/24 h, (95% CI − 23.71, − 4.13). The calcium oxalate-relative urinary supersaturation ratio 
in the overall population decreased from a mean of 11.3 (5.7) to 8.8 (3.8) (− 2.8; 95% CI − 4.9, − 0.79). This difference was 
driven by oxalate reduction alone, but not any other urinary parameters. Mean daily dietary oxalate, calcium, and fluid intake 
recorded by frequent diet recall did not differ by study periods.
Conclusion ALLN-177 reduced 24-h UOx excretion, and was well tolerated. The results of this pilot study provided justi-
fication for further investigation of ALLN-177 in patients with secondary hyperoxaluria.
Trial registration: Clinicaltrials.gov NCT02289755.
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Introduction
Secondary hyperoxaluria, a well-known risk factor for cal-
cium oxalate urolithiasis and oxalate nephropathy, can result 
from excess absorption of dietary oxalate of an unknown 
cause (idiopathic hyperoxaluria (IH)) or may occur in 
patients with enteric hyperoxaluria (EH) due to bowel dis-
ease or surgery [1, 2]. It is commonly defined as a urine 
oxalate (UOx) > 0.45 mmoL/1.73 m2/24 h, or approximately 
40 mg/24 h for adults [3].
Postulated mechanisms for IH include increased intestinal 
absorption of oxalate, increased dietary oxalate intake, and 
abnormal renal tubular excretion of oxalate [4]. Although 
patients with IH are generally thought to have milder eleva-
tions in UOx excretion compared to patients with EH, severe 
hyperoxaluria and recurrent nephrolithiasis may occur in 
either type of hyperoxaluria [5].
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EH refers to excessive UOx excretion that is a result of 
increased intestinal oxalate absorption due to fat malabsorp-
tion commonly seen as a complication of bariatric surgical 
procedures, such as the Roux-en Y gastric bypass, and in 
other conditions including such as cystic fibrosis (or from 
pancreatic insufficiency of any cause), or as a consequence 
of inflammatory bowel disease (Crohn’s disease), or short 
bowel syndrome following ileal resection for any reason [1, 
6, 7].
Epidemiologic data show the association between higher 
UOx levels and increased risk for kidney stone formation 
[8]. In more than 75% of patients with kidney stones, the 
stones are comprised of calcium oxalate salts [9]. Kidney 
stone episodes are a significant risk factor for hospitaliza-
tions, surgical procedures, and in some, progressive loss of 
kidney function, even leading to dialysis or transplantation 
[10, 11]. The overall incidence and prevalence of kidney 
stone disease are increasing in the United States and other 
parts of the Western world [12, 13]. Based on data from the 
United States National Health and Nutritional Examination 
Surveys, the prevalence in the US increased from 3.2% in 
1976–1980 to 5.2% in 1988–1994, and was 8.8% in the latest 
survey covering 2007–2010 [12]. The care of patients with 
kidney stones is quite costly, with direct costs in excess of 
4 billion dollars in 2005 [12].
Guidelines for the management of patients with calcium 
oxalate kidney stones have focused on interventions to 
reduce hypercalciuria, if present, such as with the use of thi-
azide diuretics and limiting dietary salt intake, and increas-
ing daily fluid intake. Presently, there are no approved phar-
macological therapies for treating hyperoxaluria. The only 
management of hyperoxaluria involves recommendations for 
controlling and lowering the intake of dietary oxalate and 
increasing dietary calcium intake [14, 15] However, reduc-
ing oxalate intake is not effective in all patients, especially 
in those with severe hyperoxaluria. Further, remaining on 
a low oxalate diet for a prolonged time is quite challenging 
due to the presence of oxalate in many healthy foods (e.g., 
green vegetables, nuts, grains, fruits, chocolate, etc.) and 
because of its absorption-dependent increase with a high 
salt, high fat and low calcium content diet that is typical 
for many Western countries [16]. Thus, there is an unmet 
medical need for an effective therapy for patients with sec-
ondary hyperoxaluria and its associated complications such 
as kidney stones and oxalate nephropathy.
ALLN-177 is an oral crystalline formulation of the oxa-
late specific, microbial enzyme oxalate decarboxylase. It 
is developed as an oral enzyme therapy that specifically 
degrades oxalate along the gastrointestinal (GI) tract. Based 
on the pH profile of the enzyme, oxalate metabolic path-
ways, and experiments performed in the porcine model of 
diet-induced hyperoxaluria [17], the primary site of action of 
ALLN-177 is thought to be in the upper GI tract, primarily 
in the stomach. In addition, because ALLN-177 is not 
absorbed, and retains enzymatic activity in the distal GI 
tract, it may have the potential to degrade enterically elimi-
nated oxalate secreted from the circulation into the intestine.
The effect of ALLN-177 on reducing UOx was initially 
shown in a placebo-controlled cross-over study in healthy 
volunteers with diet-induced hyperoxaluria who received 
ALLN-177 7500 units/meal, three times/day [18].
Herein, we describe a single-arm, open-label pilot study 
of ALLN-177 in subjects with secondary hyperoxaluria and 
a recent history of kidney stones to determine whether UOx 
could be reduced with daily ALLN-177 therapy. The study 
was conducted to inform the design of potential future stud-
ies in the patient population with secondary hyperoxaluria.
Methods
Study population
After IRB-approval of the study protocol, the study enrolled 
subjects at three centers across the United States. Male and 
female subjects older than 18 years of age who gave writ-
ten, informed consent and who had a history of at least 
one kidney stone in the past 2 years, UOx ≥ 36 mg/24 h, 
and estimated glomerular filtration rate (eGFR) > 60 mL/
min/1.73 m2 at screening were enrolled. Stone disease was 
defined as having a history of one or more of: radio-opaque 
stones on X-ray, history consistent with passage of a stone, 
stone surgery, or extracorporeal shockwave lithotripsy 
within the last 2 years. Subjects with primary hyperoxaluria 
or with 24-h urine collections at screening with > 30% dif-
ference in the creatinine/kg body weight ratio were excluded. 
Subjects were excluded if they had an average daily die-
tary oxalate intake of < 75 mg/day calculated from three 
diet recalls obtained during screening period, and if they 
used > 300 mg/day vitamin C for more than 10 days within 
7 days prior to screening.
Study design
This was an open-label pilot study with subjects serving as 
their own controls to obtain preliminary data on the efficacy 
of ALLN-177 in patients with secondary hyperoxaluria. The 
short duration of treatment with ALLN-177 was considered 
adequate for assessing the effect of ALLN-177, since ther-
apy is oxalate specific, and its positive effect was observed 
immediately in both normal healthy volunteers [18] and in 
preclinical studies [17]. This pilot study was also intended 
to evaluate dietary habits and compliance with dosing and 
outpatient collection of 24-h urine samples, to inform future 
studies.
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Following a screening period of 35 days during which 
two 24-h urine collections were obtained to determine eligi-
bility, subjects entered a 3-day baseline period and collected 
two consecutive 24-h urine samples. During the 4-day treat-
ment period that immediately followed the baseline period, 
patients took ALLN-177 capsules orally with meals (7500 
units/meal three times/day; total of 22,500 units daily) and 
collected consecutive 24-h urine on the last 3 days of the 
4-day treatment period. Four days after the end of treatment, 
during the follow-up period, a final one 24-h urine collection 
was obtained (Fig. 1).
Study subjects were instructed to continue to follow their 
recommended usual diet throughout the study, and dietary 
intake was assessed nine times during the study by unan-
nounced, telephone diet recalls conducted by a registered 
dietitians three dietary recalls during screening, two during 
baseline, three during treatment, and 1 at follow-up (Fig. 1). 
Throughout the study, subjects continued to use concomitant 
medications for modifying kidney stone risk factors, includ-
ing pyridoxine (vitamin B6), thiazide diuretics (chlortha-
lidone, hydrochlorothiazide, amiloride with hydrochlorothi-
azide), citrate and calcium supplements, and allopurinol, as 
long as there had been no changes in these medications for at 
least 3 months prior to study entry. Use of vitamin C, which 
is metabolized into oxalate, and the use of cholestyramine, 
which is a bile acid sequestrant, were prohibited during the 
study.
Routine clinical trial safety assessments included a physi-
cal examination, adverse event (AE) assessment, standard 
clinical laboratory testing (hematology, serum chemistry, 
and urine analysis), vital sign measurements, electrocardio-
gram testing, and concomitant medication assessment.
Laboratory and diet recall methods
The 24-h urine collections were analyzed at the University 
of Texas Southwestern, Center for Mineral Metabolism 
Urine Chemistry Laboratory using standard laboratory 
methods for urine volume, pH, calcium, citrate, chloride, 
magnesium, uric acid, ammonium, phosphate, potassium, 
creatinine and sodium, and UOx [18]. The oxalate concen-
tration was measured using a sensitive high-performance 
liquid chromatography Dionex method [19], urinary calcium 
and magnesium levels were measured using atomic absorp-
tion spectrophotometry, and Cobas Mira plus analyser was 
used for measurement of creatinine, citrate and uric acid in 
the same laboratory [20]. Calcium-oxalate relative super-
saturation was computed using the Equil2 program, and is 
provided as relative supersaturation ratio [21].
The 24-h diet recalls were performed by the Wake For-
est Baptist Health Clinical Research Unit using a standard-
ized script and a multiple-pass system for data collection. 
Participants were contacted by telephone at nine timepoints 
throughout the study and were asked to recall and report 
their dietary intake from the previous day’s 24-h period. 
Data were entered into the Nutrition Data System for 
Research (NDSR) licensed by the Nutrition Coordinating 
Center (NCC) at the University of Minnesota.
The NDSR software (version 2014) was used to analyze 
daily food and beverage intake for estimation of total daily 
oxalate, calcium, sodium, calories, fat, protein, carbohydrate 
and fluid intake collected by diet recalls [22, 23]. The NDSR 
is a comprehensive database providing estimated values for 
calcium, oxalate and other nutrients in a large number of 
food items.
Fig. 1  Study design: a phase 2, multicenter, outpatient, open label, 
single-arm study in subjects with secondary hyperoxaluria and a 
recent history of kidney stones. A total of eight 24-h urine collections 
were collected for the study. Two 24-h urines were collected during 
the 35-day screening period, 2 during the baseline period, 3 during 
the treatment period and 1 during the follow up period. A registered 
dietitian contacted the subject by telephone to complete a 24-h diet 
recall: 3 during screening, 2 during baseline, 3 during treatment, and 
1 during follow up
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Statistical methods
The primary efficacy endpoint was the mean change in 
24-h UOx excretion from baseline to ALLN-177 treatment 
[(mean baseline days 2, 6 and 3)–(mean treatment days 5, 
6, and 7)]. A secondary endpoint was the percent change 
in 24-h UOx excretion. Summary statistics, including 95% 
confidence intervals (CI) of the change from baseline, were 
pre-specified, and paired t tests comparing treatment to base-
line were derived post hoc for 24-h UOx and for the rela-
tive supersaturation ratio of calcium oxalate. Nonparametric 
Spearman correlation analysis was used to calculate the cor-
relation between baseline UOx and change in UOx (Prism 
7.0, Graph Pad Software, San Diego CA).
Results
The demographic characteristics at baseline are shown 
in Table 1. Of the 16 patients enrolled, the majority were 
male, and most were Caucasian, and obese and with a pre-
served eGFR (> 60). Five (31%) had EH associated with 
bariatric surgery (three with adjustable banding, one sleeve 
gastrectomy, one Roux-en-Y procedure); while the remain-
ing eleven subjects had IH. The mean (SD) length of time 
since onset of kidney stone disease was 13.7 (12.7) years. 
Concomitant medications relevant to kidney stone risk factor 
reduction included calcium supplements (n = 5), potassium 
citrate (n = 5), thiazide diuretics (n = 3), allopurinol (n = 2) 
and pyridoxine (n = 1). Compliance with the ALLN-177 
treatment and with the 24-h urine collections was 100%. 
Diet recall compliance was > 90% in all.
The results were analyzed by all subjects and by the type 
of hyperoxaluria (Table 2).
Eleven of 16 (69%) of the study subjects had a reduc-
tion in 24-h UOx, ranging between 5 and 69 mg/24 h. The 
magnitude of reduction was correlated with the severity 
of hyperoxaluria (rs = − 0.702, p = 0.003). The individual 
changes in 24-h UOx during treatment with ALLN-177 rela-
tive to baseline are shown in Fig. 2.
Table 1  Baseline demographic and clinical characteristics
eGFR estimated glomerular filtration rat, SD standard deviation
Characteristics Enrolled n = 16
Sex—n (%)
 Male 9 (56.3)
 Female 7 (43.8)
Age at screening—years
 Mean ± SD (median) 54.1 ± 14.5 (58)
Body mass index (BMI)—(kg/m2)
 Mean ± SD (median) 32.3 ± 7.7 (32.8)
Race—n (%)
 White/Caucasian 14 (87.5%)
 Black/African American 2 (12.5%)
eGFR (mL/min/1.73 m2)
 Mean ± SD 85.1 ± 20.9
Table 2  Summary of 24-h urine 
oxalate excretion (mg/24 h), 
percent change overall and by 
type of hyperoxaluria
Data are shown mean (SD)
EH enteric hyperoxaluria, IH idiopathic hyperoxaluria
*p<0.05 for difference between baseline and treatment period
Groups Baseline period 
mean (SD)
Treatment 
period mean 
(SD)
Change from baseline 
mean (SD), (%)
Follow-up mean (SD)
All subjects (n = 16) 77.7 (55.9) 63.7 (40.1)* − 13.9 (18.4), − 13.3 77.5 (49.2)
EH subjects (n = 5) 110.5 (82.9) 88.5 (57.1) − 22.0 (26.6), − 10.4 109.8 (71.9)
IH subjects (n = 11) 62.7 (33.8) 52.5 (25.6) − 10.2 (13.3), − 14.6 62.7 (28.2)
Fig. 2  Change in mean urinary oxalate during ALLN-177 treatment 
compared to baseline values. Shown is a scatter plot of the baseline 
24-h UOx on the X axis versus the 24-h UOx during ALLN-177 
treatment on the Y axis; each diamond shape represents an individual 
study subject. The nonparametric Spearman’s correlation coefficient 
was r = − 0.702, p = 0.003
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The calculated mean (SD) calcium oxalate supersatura-
tion for the overall study population decreased during treat-
ment from 11.3 (5.7) to 8.8 (3.8) (mean change − 2.8; 95% 
CI − 4.9; − 0.79). The average 24-h urine pH, calcium, cit-
rate, magnesium and other stone risk parameters remained 
stable throughout the study (Table 3).
Analysis of the diet recall data revealed that subjects con-
sumed a mean (SD) of 201.1 (121.9) mg of oxalate per day 
at baseline, and this did not meaningfully change during the 
4 days on ALLN-177 therapy, nor during follow-up (187.4 
(130) mg/d and 193.0 (139.4) mg/d, respectively). The mean 
(SD) daily calcium, sodium and fluid intake during treat-
ment were 796.2 (303.4) mg, 3.56 (1.3) g, and 3.2 (1.1) L 
respectively, which was very similar to baseline and follow-
up levels (data not shown). The mean (SD) daily calorie 
intake at baseline was 2301.9 (939.1) kcal and on treatment 
was 1989.6 (713.2), with fat comprising 37.8% and protein 
14.7% of daily calories, and which did not change during 
the study.
ALLN-177 therapy appeared to be well tolerated. Nine 
subjects (56.3%) reported AEs, all of mild or moderate 
severity; none was a serious AE or led to study drug ces-
sation or subject withdrawal. Only 2 (12.5%) subjects’ AEs 
were considered possibly related or related to study drug and 
were resolved within 1 day; these included abdominal dis-
tension, dyspepsia and nausea in one subject, and abdominal 
distension and flatulence in another subject. The evaluation 
of routine laboratory biochemical examinations, physical 
examinations, electrocardiograms, and vital signs (blood 
pressure and pulse rate) revealed no safety concerns (data 
not shown).
Discussion
This open-label, short, pilot study was designed to evalu-
ate whether ALLN-177, as an oral enzyme therapy taken 
with meals, could reduce 24-h UOx excretion in patients 
with histories of kidney stones and secondary hyperoxalu-
ria and it was conducted to inform future studies.
The results of this study were comparable to the find-
ings from preclinical studies [17], and the Phase 1 study in 
normal healthy volunteers with diet-induced hyperoxaluria 
[18]. ALLN-177 was well-tolerated. All subjects finished 
the study, and there were no serious or severe AEs; most 
were transient GI symptoms. A mean reduction in UOx of 
about 14 mg/24 h (13%) was observed during the 4-day 
treatment, and this was associated with a mean reduction 
in the calcium oxalate relative supersaturation ratio with 
no substantive changes in the other urinary parameters, 
suggesting that the effect of ALLN-177 is immediate 
and oxalate specific. The return of 24-h UOx excretion 
to baseline levels after discontinuation of ALLN-177 was 
expected, given its mechanism of action of immediate deg-
radation of oxalate locally in the GI tract.
There appeared to be a relationship between the mag-
nitude of reduction in 24-h Uox during treatment and the 
severity of hyperoxaluria at baseline (Fig.  2). Among 
the 11 subjects who had a reduction in UOx of > 5 mg/
day while on ALLN-177, the mean baseline Uox was 
91.7  mg/24  h, compared with 46.8  mg/24  h recorded 
among the 5 subjects without a change in UOx. This rela-
tionship was observed in both the EH and IH patients.
Table 3  Summary of 24-h urine 
biochemistries by study period
Data are shown as mean (SD). RSR of calcium oxalate calculated using equil2
CaOx calcium oxalate, RSR relative supersaturation ratio
*p<0.05 for difference between baseline and treatment period
Parameter Baseline period mean 
(SD) n = 16
Treatment period mean 
(SD) n = 16
Follow-up 
mean (SD) 
n = 16
Calcium (mg/24 h) 204.2 (103.6) 205.1 (100.6) 203.6 (100.9)
Magnesium (mg/24 h) 143.8 (80.3) 141.4 (68.8) 138.3 (57.9)
Citrate (mg/24 h) 547.1 (350.7) 553.3 (351.5) 541.8 (403.3)
Creatinine (mg/24 h) 1609.3 (482.3) 1577.7 (490.9) 1588.4 (466.0)
Uric acid (mg/24 h) 572.3 (169.0) 585.2 (214.1) 566.9 (167.4)
Ammonium (meq/24 h) 39.1 (17.37) 39.5 (16.8) 41.8 (17.1)
Phosphate (mg/24 h) 1105.4 (382.7) 1033.9 (441.0) 1096.8 (359.7)
Potassium (meq/24 h) 70.2 (31.6) 68.7 (40.0) 71.6 (40.9)
Sodium (meq/24 h) 163.1 (52.8) 185 (60.6) 168.9 (62.6)
pH 5.96 (0.3) 6.029 (0.3) 5.915 (0.4)
Urine volume (L) 1.84 (0.5) 2.1 (0.6) 2.2 (0.9)
RSR CaOx 11.6 (5.7) 8.8 (3.8)* 10.8 (5.4)
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Endogenous production of oxalate generally does not 
exceed 20–25 mg/24 h, and therefore, in the absence of a pri-
mary metabolic defect, high daily UOx is most likely due to 
over absorption of oxalate from the diet, consistent with the 
current understanding of the pathophysiology of secondary 
hyperoxaluria [24]. Thus, patients with higher UOx levels at 
baseline are possibly absorbing more oxalate than patients 
with lower UOx, and therefore are more likely to respond 
to a therapy that degrades oxalate in the GI tract. Therapy 
was observed to be oxalate-specific since UOx returned to 
baseline values at the end of the 4-day follow-up period, and 
no other measured stone risk factors in the urine changed 
during treatment with ALLN-177 (Table 2).
The magnitude of reduction in UOx with ALLN-177 
could be regarded as modest. However, given the patho-
physiology of oxalate-related renal injury, such a reduction, 
if sustained over a long period of time, could potentially 
reduce calcium oxalate crystalluria and subsequent kidney 
stone formation, and other oxalate-induced renal injury [25, 
26]. Epidemiologic data suggests that the lower the UOx, the 
lower the likelihood of being a stone former [8]. Therefore, 
even a modest reduction in UOx could be important thera-
peutically if sustained over time.
Five subjects (three with IH and two with EH) out of 16 
did not have a change in UOx excretion with ALLN-177 
therapy (Fig. 2). Given the variability of secondary hyper-
oxaluria and the design of this pilot study, the precise rea-
sons for the individual variations of oxalate excretion and 
response to oral enzyme therapy in these patients is open 
to speculation. It may have been associated with diet and 
the subject’s individual variation related to stomach pH, 
retention time of food in the stomach, the bioavailability of 
oxalate from their diets, and the passage rate of ALLN-177 
from the stomach to the intestine, among others.
Limitations of this study include its short duration, the 
small study population number, and an open-label uncon-
trolled design. The design was intentional and directed to 
inform future studies regarding endpoint selection, clinical 
activity, duration, study procedures and drug compliance 
among others, and thus a placebo control was not included 
in the study design. Of note, ALLN-177 is a specific enzyme 
therapy and its effect is immediate as shown in the initial 
proof of principle study of ALLN-177 in healthy volunteers 
[18]. Thus, we speculated that 4 days of treatment would be 
sufficient to show a positive effect. We also acknowledge that 
the colonization status of Oxalobacter formigenes, thought 
to possibly be a factor in limiting dietary oxalate absorption 
and reducing hyperoxaluria, was not examined [27, 28].
In the study, diet recall based on NSDR software design 
by Nutrition Coordinating Center University Minnesota was 
used to asses daily dietary changes. Dietary recalls, rather 
than patient maintained dietary records were collected to 
reduce participant burden as well as to limit participants 
from possibly changing their dietary behavior and thus bias 
recording of intakes. It is acknowledged that all forms of 
dietary assessment including direct observation are subject 
to error; however, the multiple-pass 24-h diet recall used for 
this study is often recommended as the method of choice 
for estimating dietary intake and is being utilized more fre-
quently in research [22, 29, 30]. When conducted by trained 
interviewers using standardized methods, as in the current 
study, results tend to be more accurate than a standard 7 day 
food diary and importantly, present less burden to patients 
[30]. The NDSR was used in this study not only because of 
its rigorous and robust status as a research tool, but because 
of its uniquely comprehensive database to include complete 
and estimated values for calcium and oxalate in different 
food sources.
At present, there is no specific pharmacological therapy 
to reduce urinary oxalate excretion. Therapeutic agents 
that have been used in an attempt to lower UOx excretion 
in patients with hyperoxaluria have included sevelamer, a 
non-specific oxalate binder [31], lactic acid bacteria [32, 
33] and a bacterial paste from O. formigenes that is specu-
lated to degrade oxalate in the gut [34]. In an open-label, 
non-randomized study, a probiotic given to patients with 
EH had a transient effect in lowering UOx, and the UOx 
values returned to pre-treatment levels after 3 months of 
treatment [35]. Similarly, in a randomized, double-blind, 
placebo-controlled study, a probiotic (Oxadrop®) given 
to ten patients with calcium stones and IH had no effect 
on UOx excretion [35]. In another study, ten subjects with 
EH were enrolled in a non-randomized, open-label study of 
sevelamer hydrochloride for 7 days, and no change in UOx 
was demonstrated [31]. Lastly, in a 4-week study of patients 
with mild hyperoxaluria and kidney stones on a controlled 
metabolic low oxalate diet, the use of two different probiot-
ics preparation did not affect Uox, but rather the diet itself 
had a positive effect [36].
In the absence of a more specific therapy, dietary recom-
mendations for management include reduced dietary oxalate, 
salt, and protein, increased calcium intake and the use of 
dietary calcium supplements, and high-fluid intake. Adher-
ence to these recommendations is quite difficult to main-
tain, especially in the EH population [37]. Although, dietary 
oxalate restriction using a controlled diet for a short time 
can lead to a reduction in UOx excretion in patients with 
mild hyperoxaluria [36], sustained effectiveness of dietary 
changes in patients with more severe hyperoxaluria remains 
to be determined. Oxalate is ubiquitous in many foods in 
the American Western diet [16, 36], and it is not clear that 
patients outside of a clinical trial can easily adhere to die-
tary recommendations that might reduce UOx, either due to 
limited availability of oxalate-free foods, lifestyle choices, 
or the economic costs of such specific diets. Additionally, 
methods of food preparation may affect the soluble oxalate 
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content as well, such that even the same food prepared differ-
ently may yield different oxalate content [38]. Importantly, 
even with dietary counselling and adherence to a low oxa-
late dietary intake, many patients with hyperoxaluria after 
bariatric or other bowel surgery remain hyperoxaluric and 
develop stones and CKD [6, 7].
There remains an unmet medical need for an effective 
therapy for patients with secondary hyperoxaluria and its 
associated complications such as kidney stones and oxalate 
nephropathy. In our study, with patients with hyperoxaluria 
and a calcium-oxalate kidney stone history on their usual 
diets and standard of care including calcium supplements 
and thiazide diuretics, oral therapy with ALLN-177 also 
reduced the calcium-oxalate relative supersaturation ratio. 
This was driven by the reduction in UOx excretion, as other 
measured urine analytes did not change. Based on dietary 
assessment of food intake throughout the study, there were 
no substantive changes in dietary oxalate, calcium, sodium, 
or protein that would help explain the observed reduction in 
UOx or the relative urinary supersaturation ratio.
In conclusion, in this initial uncontrolled study in a small 
group of patients with secondary hyperoxaluria, oral enzyme 
therapy appears to be well-tolerated and reduced UOx by an 
average of 14 mg/24 h, without impacting other measured 
24-h urine stone risk parameters. Subsequent longer-term 
clinical trials in subjects with secondary hyperoxaluria and 
kidney stones are underway.
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